Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

In the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death, and increased eligibility for treatment-free r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kantarjian, Hagop M., Hughes, Timothy P., Larson, Richard A., Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Boquimpani, Carla, Pasquini, Ricardo, Clark, Richard E., Dubruille, Viviane, Flinn, Ian W., Kyrcz-Krzemien, Slawomira, Medras, Ewa, Zanichelli, Maria, Bendit, Israel, Cacciatore, Silvia, Titorenko, Ksenia, Aimone, Paola, Saglio, Giuseppe, Hochhaus, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862065/
https://www.ncbi.nlm.nih.gov/pubmed/33414482
http://dx.doi.org/10.1038/s41375-020-01111-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862065/
https://www.ncbi.nlm.nih.gov/pubmed/33414482
http://dx.doi.org/10.1038/s41375-020-01111-2

Ejemplares similares